Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B31/00—Preparation of derivatives of starch
  • C08B31/08—Ethers
  • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
  • C08B31/125—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch having a substituent containing at least one nitrogen atom, e.g. cationic starch
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

• This invention relates to certain dextrin derivatives, the treatment of acidic conditions and to compositions for the use in such treatment.
• a dextrin derivative in which a proportion of the hydroxyl groups of dextrin are replaced by basic groups.
• Such basic groups may be any groups capable of binding acidic moieties present in body compartments such as the intestine, the peritoneum or the blood compartment.
• a preferred basic group is an amine group, more preferably a tertiary amine or a quaternary ammonium group.
• Cholestyramine is the chloride salt of a basic anion- exchange resin in which the anion-exchange sites are provided by quaternary ammonium groups.
• the other agent is a resin called colestipol hydrochloride, a copolymer of diethyl pentamine and epichlo ohydr in. Both these materials are hydrophilic but insoluble in water.
• Another problem with these known agents is that they may also bind other compounds in the intestine including drugs administered concurrently.
• Acid poisoning can occur as a result not only of the assimilation of substances which are normally regarded as poisons but also of pharmaceutical preparations which can be poisonous if taken in overdose.
• acid poisons include acetylsalicylic acid (aspirin) and barbiturates such as amylobarbitone, butobar b i tone , pen tobar b i tone , phenobarbitone and quinalbarbitone.
• the present invention accordingly also provides the use of the dextrin derivative to lower blood cholesterol levels and to treat acid poisoning.
• the present invention further provides a pharmaceutical composition comprising the dextrin derivative of the invention together with a inert carrier or diluent therefor.
• the present invention provides a method for lowering blood cholesterol levels or treating acid poisoning in an animal subject, including a human being, comprising administering to the animal subject an effective amount of a dextrin derivative of the invention.
• the invention provides a method of making a pharmaceutical composition of the invention comprising formulating together a dextrin derivative of the invention together with at least one inert carrier or diluent .
• Dextrin is made by hydrolysis of starch, typically by treatment of various starches with dilute acids or by heating a dry starch. Such methods produce glucose polymers with a wide range of polymerisation.
• the degree of polymerisation (D.P) varies from one or two up to comparatively high numbers.
• the direct hydrolysis product of starch might contain up to 60% by weight of material having a D.P less than 12.
• the dextrin derivative contains a relatively high proportion of glucose polymers of D.P. greater than 12.
• the dextrin derivative contains at least 50% by weight of glucose polymers of D.P. greater than 12.
• the dextrin derivative contains less than 10% by weight of glucose polymers having a D.P. less than 12. Most preferably the dextrin derivative contains less than 5% by weight of glucose polymers having a D.P. less than 12.
• Such dextrin derivatives are prepared from dextrin which has been fractionated to remove dextrin with a low D.P. Known fractionation techniques may be used including solvent precipation and membrane fractionation.
• a method of preparing a glucose polymer mixture is described in GB 2132914 and a method for the preparation of a glucose polymer mixture with a relatively low proportion of low D.P glucose polymers is described in Example 2 of GB 2154469.
• This mixture contains 91.9% of polymers having a degree of polymerisation greater than* 12 and 7.9% of polymers having a degree of polymerisation from 2 to 10.
• the weight average molecular weight of the dextrin derivative of use in the present invention is preferably from 15,000 to 25,000, more preferably from 15,000 to 20,000.
• the number average molecular weight is preferably less than 5,000.
• the weight average molecular weight is determined by high pressure liquid chromatography (HP C) . The method is carried out on dextrin (rather than the dextrin derivative) using chromatographic columns calibrated with dextran standards, as described by Alsop et al, J. Chromatography 246, 227-240 (1982).
• the very high molecular weight glucose polymers are not present or are only present in small amounts in the dextrin derivative mixture.
• composition in accordance with the present invention may be made up for administration by any suitable route.
• the composition may be for oral administration or, in the case of treatment of acid poisoning, for administration via the peritoneum.
• Basic derivatives of dextrin represent new chemical compounds. They can be prepared in various ways. For instance, they may be prepared by methods analogous to those described for the preparation of ethers having a tertiary amine group as described in US 2813093, US 2917506, US 2935436 and US 2975124, or, for the preparation of quaternary ammonium compounds, as described in US 2876217.
• the properties of basic derivatives of dextrin depend on the nature and content of the basic groups. It is preferred that the derivative is water soluble.
• the content of the basic group is preferably at least 5% by weight, the upper limit being determined in practice by the difficulty of introducing much more than 10% by weight of the basic group into the dextrin, using currently available techniques.
• compositions containing derivatives of dextrin can be used. These compositions have the advantage that they are water soluble and their taste or colour can be disguised by adding, for instance, synthetic food additives.
• the active material By drinking a mixture containing the dextrin derivative the active material immediately reaches the intestine where it acts to bind bile acids or acid poisions.
• the rapid delivery of the active ingredient to its target, the bile acids or the the acid poisons has the advantage that no degeneration occurs before the active ingredient reaches the site of the target.
• a composition for peritoneal administration may also include electrolytes similar to those contained in conventional solutions used in peritoneal dialysis. For example, they may include electrolytes in the following concentration (all in mmol/1):-
• electrolytes are, however, not so important as in conventional peritoneal dialysis, because the treatment of cholesterol levels or of acid poisoning is a short-term operation. Nevertheless, electrolyte imbalance can cause serious problems in poisoned patients, and the present of suitable electrolytes in the dialysis is recommended.
• compositions of the invention contain an osmotic agent in a concentration capable of producing efficient and sustained ultrafiltration (a term used to mean the net flow of fluid across the peritoneal membrane into the peritoneal cavity).
• the osmotic agent in the compositions of the invention is normally the dextrin derivative itself, although it can be supplemented, when appropriate, by the inclusion of other osmotic agents, for example dextrose or a mixture of glucose polymers.
• a quaternary ammonium alkyl dextrin (specifically quaternary ammonium hydroxyethyl dextrin) was prepared in the following manner. Triethylamine (45 g) was suspended in water (100 ml) and stirred at room temperature. Then epichlorohydrin (37g, 0.4 mole) was added dropwise. Stirring was continued for 5 hours but the mixture was still not homogeneous. After stirring overnight the resultant homogeneous solution was evaporated at 30°C in vacuo to a thick syrup over several hours.
• the substituted dextrin can accordingly be used to lower blood cholesterol levels but without the above mentioned disadvantages associated with the use of cholestyramine .
• Rats were dosed intravenously with radio-labelled phenobarbitone and after 15 minutes 10 ml of a 2% solution of the dextrin derivative was introduced into the peritoneum. For comparison a 2% solution of unsubstituted dextrin was used as a control. The experiment was conducted on two occasions with 3 animals in each treatment group. One hour after the introduction of the solutions into the peritoneal cavity, simultaneous samples of blood and peritoneal fluid were obtained and analysed for radio- labelled phenobarbitone. Peritoneal fluid/blood plasma ratios for phenobarbitone at 3 hours are given below.
• Dialysate Dialysate fluid/blood plasma ratio

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Biochemistry (AREA)
• Polymers & Plastics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Hematology (AREA)
• Pharmacology & Pharmacy (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Materials Engineering (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Steroid Compounds (AREA)
• Saccharide Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Eye Examination Apparatus (AREA)
• Separation Using Semi-Permeable Membranes (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10641334

Family Applications (2)

Family Applications After (1)

Country Status (18)

Families Citing this family (4)

Family Cites Families (15)

• 1988
  • 1988-07-29 GB GB888818116A patent/GB8818116D0/en active Pending
• 1989
  • 1989-07-27 YU YU150589A patent/YU47421B/sh unknown
  • 1989-07-27 ZA ZA895705A patent/ZA895705B/xx unknown
  • 1989-07-28 AT AT89307738T patent/ATE122058T1/de not_active IP Right Cessation
  • 1989-07-28 US US07/640,313 patent/US5280017A/en not_active Expired - Fee Related
  • 1989-07-28 EP EP89909226A patent/EP0427779A1/en active Pending
  • 1989-07-28 WO PCT/GB1989/000858 patent/WO1990001499A1/en active IP Right Grant
  • 1989-07-28 ES ES89307738T patent/ES2072904T3/es not_active Expired - Lifetime
  • 1989-07-28 EP EP89307738A patent/EP0356024B1/en not_active Expired - Lifetime
  • 1989-07-28 JP JP1508598A patent/JPH04500976A/ja active Pending
  • 1989-07-28 DE DE68922445T patent/DE68922445T2/de not_active Expired - Fee Related
  • 1989-07-28 AU AU40508/89A patent/AU626074B2/en not_active Ceased
  • 1989-07-31 PT PT91332A patent/PT91332B/pt not_active IP Right Cessation
  • 1989-07-31 CA CA000607119A patent/CA1337517C/en not_active Expired - Fee Related
  • 1989-07-31 NZ NZ230147A patent/NZ230147A/xx unknown
• 1990
  • 1990-12-28 DK DK308990A patent/DK308990A/da not_active Application Discontinuation
• 1991
  • 1991-01-21 FI FI910296A patent/FI100534B/fi active
  • 1991-01-28 NO NO910316A patent/NO910316D0/no unknown
• 1992
  • 1992-09-29 HR HRP920595 patent/HRP920595A2/hr not_active Application Discontinuation
• 1993
  • 1993-11-12 US US08/150,717 patent/US5439894A/en not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events